SGO 2019: TWiST Backs Benefits of PARP Inhibitor in Ovarian Cancer

Leggi l'articolo originale


The TWiST analysis of the phase III ENGOT-OV16/NOVA trial evaluated the time without symptoms or toxicity for niraparib vs placebo in patients with recurrent ovarian cancer.

Lascia un commento